{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.9","upperLimit":"33.9","value":"24.9"},{"groupId":"OG001","lowerLimit":"10.9","upperLimit":"22.4","value":"13.9"},{"groupId":"OG002","lowerLimit":"11.1","upperLimit":"30.3","value":"22.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"81"},{"groupId":"OG002","value":"60"}],"units":"Participants"}],"description":"PFS is the time from first dose to the first documented progressive disease (PD) or death due to any cause, whichever occurs first assessed by the investigator based on the IWG criteria. For those who have PD, the true date of disease progression was approximated by the date of the first assessment at which PD is objectively documented per IWG criteria, regardless of discontinuation of study drug. Death is always considered as a confirmed PD event. The non-parametric Kaplan-Meier method was used to estimate the PFS curve with missing data censored at last assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with RRcHL who failed to achieve a response or progressed after auto-SCT and have relapsed after treatment with or failed to respond to BV post auto-SCT received pembrolizumab, 200 mg, intravenously (IV) every 3 weeks (Q3W) on Day 1 of each 21-day cycle up to 35 cycles, for up to 24 months.","id":"OG000","title":"Cohort 1"},{"description":"Participants with RRcHL who were unable to achieve Complete Response (CR) or Partial Response (PR) to salvage chemotherapy and did not receive auto-SCT, but have relapsed after treatment with or failed to respond to BV received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle up to 35 cycles, for up to 24 months.","id":"OG001","title":"Cohort 2"},{"description":"Participants with RRcHL who failed to achieve a response to or progressed after auto-SCT and have not received BV post auto-SCT received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle, up to 35 cycles for up to 24 months. These participants may or may not have received BV as part of primary treatment or salvage treatment.","id":"OG002","title":"Cohort 3"}],"paramType":"MEDIAN","populationDescription":"All allocated participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 99 months","title":"Progression-free Survival (PFS) Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"Months"}